BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 21315644)

  • 1. [Locally advanced unresectable pancreatic cancer: Induction chemoradiotherapy followed by maintenance gemcitabine versus gemcitabine alone: Definitive results of the 2000-2001 FFCD/SFRO phase III trial].
    Barhoumi M; Mornex F; Bonnetain F; Rougier P; Mariette C; Bouché O; Bosset JF; Aparicio T; Mineur L; Azzedine A; Hammel P; Butel J; Stremsdoerfer N; Maingon P; Bedenne L; Chauffert B
    Cancer Radiother; 2011 Jun; 15(3):182-91. PubMed ID: 21315644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study.
    Chauffert B; Mornex F; Bonnetain F; Rougier P; Mariette C; Bouché O; Bosset JF; Aparicio T; Mineur L; Azzedine A; Hammel P; Butel J; Stremsdoerfer N; Maingon P; Bedenne L
    Ann Oncol; 2008 Sep; 19(9):1592-9. PubMed ID: 18467316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
    Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L
    Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance chemotherapy after chemoradiation improves survival of patients with locally advanced pancreatic carcinoma: a retrospective analysis of prospectively recruited patients.
    Brunner TB; Tinkl D; Grabenbauer GG; Meyer T; Brueckl WM; Sauer R
    Strahlenther Onkol; 2006 Apr; 182(4):210-5. PubMed ID: 16622622
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer.
    Heinemann V; Quietzsch D; Gieseler F; Gonnermann M; Schönekäs H; Rost A; Neuhaus H; Haag C; Clemens M; Heinrich B; Vehling-Kaiser U; Fuchs M; Fleckenstein D; Gesierich W; Uthgenannt D; Einsele H; Holstege A; Hinke A; Schalhorn A; Wilkowski R
    J Clin Oncol; 2006 Aug; 24(24):3946-52. PubMed ID: 16921047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
    Mukherjee S; Hurt CN; Bridgewater J; Falk S; Cummins S; Wasan H; Crosby T; Jephcott C; Roy R; Radhakrishna G; McDonald A; Ray R; Joseph G; Staffurth J; Abrams RA; Griffiths G; Maughan T
    Lancet Oncol; 2013 Apr; 14(4):317-26. PubMed ID: 23474363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.
    Colucci G; Giuliani F; Gebbia V; Biglietto M; Rabitti P; Uomo G; Cigolari S; Testa A; Maiello E; Lopez M
    Cancer; 2002 Feb; 94(4):902-10. PubMed ID: 11920457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of bevacizumab with concurrent capecitabine and radiation followed by maintenance gemcitabine and bevacizumab for locally advanced pancreatic cancer: Radiation Therapy Oncology Group RTOG 0411.
    Crane CH; Winter K; Regine WF; Safran H; Rich TA; Curran W; Wolff RA; Willett CG
    J Clin Oncol; 2009 Sep; 27(25):4096-102. PubMed ID: 19636002
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study.
    Iannitti D; Dipetrillo T; Akerman P; Barnett JM; Maia-Acuna C; Cruff D; Miner T; Martel D; Cioffi W; Remis M; Kennedy T; Safran H
    Am J Clin Oncol; 2005 Dec; 28(6):570-5. PubMed ID: 16317266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction chemotherapy with gemcitabine, oxaliplatin, and 5-fluorouracil/leucovorin followed by concomitant chemoradiotherapy in patients with locally advanced pancreatic cancer: a Taiwan cooperative oncology group phase II study.
    Ch'ang HJ; Lin YL; Wang HP; Chiu YF; Chang MC; Hsu CH; Tien YW; Chen JS; Hsieh RK; Lin PW; Shan YS; Cheng AL; Chang JY; Whang-Peng J; Hwang TL; Chen LT
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e749-57. PubMed ID: 21420250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.
    Landry J; Catalano PJ; Staley C; Harris W; Hoffman J; Talamonti M; Xu N; Cooper H; Benson AB
    J Surg Oncol; 2010 Jun; 101(7):587-92. PubMed ID: 20461765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial.
    Loehrer PJ; Feng Y; Cardenes H; Wagner L; Brell JM; Cella D; Flynn P; Ramanathan RK; Crane CH; Alberts SR; Benson AB
    J Clin Oncol; 2011 Nov; 29(31):4105-12. PubMed ID: 21969502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival with nal-IRI (liposomal irinotecan) plus 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin in per-protocol and non-per-protocol populations of NAPOLI-1: Expanded analysis of a global phase 3 trial.
    Chen LT; Siveke JT; Wang-Gillam A; Li CP; Bodoky G; Dean AP; Shan YS; Jameson GS; Macarulla T; Lee KH; Cunningham D; Blanc JF; Chiu CF; Schwartsmann G; Braiteh FS; Mamlouk K; Belanger B; de Jong FA; Hubner RA
    Eur J Cancer; 2018 Dec; 105():71-78. PubMed ID: 30414528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.
    Van Laethem JL; Hammel P; Mornex F; Azria D; Van Tienhoven G; Vergauwe P; Peeters M; Polus M; Praet M; Mauer M; Collette L; Budach V; Lutz M; Van Cutsem E; Haustermans K
    J Clin Oncol; 2010 Oct; 28(29):4450-6. PubMed ID: 20837948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective study of cetuximab and gemcitabine in combination with radiation therapy: feasibility and efficacy in locally advanced pancreatic head cancer.
    Fiore M; Trodella L; Valeri S; Borzomati D; Floreno B; Ippolito E; Trecca P; Trodella LE; D'Angelillo RM; Ramella S; Coppola R
    Radiat Oncol; 2015 Dec; 10():255. PubMed ID: 26670587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomised phase II study.
    Wilkowski R; Boeck S; Ostermaier S; Sauer R; Herbst M; Fietkau R; Flentje M; Miethe S; Boettcher HD; Scholten T; Bruns CJ; Rau HG; Hinke A; Heinemann V
    Br J Cancer; 2009 Dec; 101(11):1853-9. PubMed ID: 19904268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer -- feasible and effective].
    Wilkowski R; Thoma M; Heinemann V; Rau HG; Wagner A; Stoffregen C; Dühmke E
    Strahlenther Onkol; 2003 Feb; 179(2):78-86. PubMed ID: 12590317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer.
    Joensuu TK; Kiviluoto T; Kärkkäinen P; Vento P; Kivisaari L; Tenhunen M; Westberg R; Elomaa I
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):444-52. PubMed ID: 15380578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome.
    Spry N; Harvey J; Macleod C; Borg M; Ngan SY; Millar JL; Graham P; Zissiadis Y; Kneebone A; Carroll S; Davies T; Reece WH; Iacopetta B; Goldstein D
    Int J Radiat Oncol Biol Phys; 2008 Apr; 70(5):1438-46. PubMed ID: 18164859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.